MUC1 is a transmembrane glycoprotein and member of the mucin family. It is linked to different function in both normal and cancer cells. In normal epithelial cells of the mucous membrane, it provides lubrication and protection, however abnormal expression of MUC1 is involved in cancer development, invasion and metastasis. It is reported that the upregulation of MUC1 is associated with progression of various epithelial cancer types such as breast, pancreatic, liver, and lung and studies suggest its involvement as a specific target for immunotherapy.
Anti-MUC1-SAP is a bonded toxin between a biotinylated antibody to MUC1 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
MUC1-SAP eliminates cells expressing human MUC1. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Mouse (Cat. #IT-74)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: Saporin, MUC1, mucin, glycoprotein, cancer, epithelial, mucous membrane, immunotherapy